Table 3.

HPV, Stage and Disease Site Stratified Analysis

	Never Statin User			Ever Statin user
Effect Modifiers	No. of Events	Person Months	HR (95% CI)a	No. of Events	Person Months	HR (95% CI)a
HPV status
Overall Death
HPV-Positive	61	12943.93	1 (REF)	21	7660.39	0.52 (0.31, 0.86)
HPV-Negative	131	12916.80	1 (REF)	80	7560.38	0.76 (0.57, 1.02)
P for interaction	0.18
Disease-Specific Death
HPV-Positive	38	12943.93	1 (REF)	10	7660.39	0.41 (0.21, 0.84)
HPV-Negative	71	12916.80	1 (REF)	52	7560.38	1.04 (0.71, 1.51)
P for interaction	0.02
Recurrence
HPV-Positive	55	8814.55	1 (REF)	18	5798.21	0.49 (0.29, 0.84)
HPV-Negative	95	8996.63	1 (REF)	68	5028.99	1.03 (0.74, 1.43)
P for interaction	0.02
Stage
Overall Death
Stage 4	313	34729.56	1 (REF)	155	17522	0.68 (0.56, 0.83)
Stage 0–3	119	20898.04	1 (REF)	70	12325.95	0.82 (0.61, 1.10)
P for interaction	0.32
Disease-Specific Death
Stage 4	195	34729.56	1 (REF)	97	17522	0.74 (0.58, 0.96)
Stage 0–3	55	20898.04	1 (REF)	32	12325.95	0.83 (0.54, 1.29)
P for interaction	0.67
Recurrence
Stage 4	237	21384.74	1 (REF)	120	11211.86	0.78 (0.62, 0.99)
Stage 0–3	81	13268.40	1 (REF)	57	8230.54	0.99 (0.70, 1.39)
P for interaction	0.26
Disease Site
Overall Death
Oropharynx	144	23395.71	1 (REF)	64	12503.82	0.64 (0.48, 0.87)
Other site	288	32231.89	1 (REF)	161	17344.13	0.80 (0.66, 0.98)
P for interaction	0.22
Disease-Specific Death
Oropharynx	87	23395.71	1 (REF)	35	12503.82	0.64 (0.43, 0.96)
Other site	163	32231.89	1 (REF)	94	17344.13	0.87 (0.67, 1.13)
P for interaction	0.21
Recurrence
Oropharynx	111	14423.62	1 (REF)	44	8470.44	0.62 (0.43, 0.88)
Other site	207	20229.52	1 (REF)	133	10971.96	0.99 (0.79, 1.24)
P for interaction	0.02

^aAdjusted for Age at diagnosis, BMI and ACE-27